vs

Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and Kiniksa Pharmaceuticals International, plc (KNSA). Click either name above to swap in a different company.

Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($346.7M vs $202.1M, roughly 1.7× Kiniksa Pharmaceuticals International, plc). Dolby Laboratories, Inc. runs the higher net margin — 15.4% vs 7.0%, a 8.4% gap on every dollar of revenue. On growth, Kiniksa Pharmaceuticals International, plc posted the faster year-over-year revenue change (65.0% vs -2.9%). Kiniksa Pharmaceuticals International, plc produced more free cash flow last quarter ($53.3M vs $50.2M). Over the past eight quarters, Kiniksa Pharmaceuticals International, plc's revenue compounded faster (59.1% CAGR vs -2.5%).

Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.

Kiniksa Pharmaceuticals International plc is a global biopharmaceutical firm focused on discovering, developing and commercializing targeted therapies for patients with unmet medical needs, primarily in autoimmune, inflammatory and rare disease segments. It operates across major markets including North America, Europe and Asia, advancing a pipeline of clinical-stage and approved treatment candidates.

DLB vs KNSA — Head-to-Head

Bigger by revenue
DLB
DLB
1.7× larger
DLB
$346.7M
$202.1M
KNSA
Growing faster (revenue YoY)
KNSA
KNSA
+67.8% gap
KNSA
65.0%
-2.9%
DLB
Higher net margin
DLB
DLB
8.4% more per $
DLB
15.4%
7.0%
KNSA
More free cash flow
KNSA
KNSA
$3.1M more FCF
KNSA
$53.3M
$50.2M
DLB
Faster 2-yr revenue CAGR
KNSA
KNSA
Annualised
KNSA
59.1%
-2.5%
DLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DLB
DLB
KNSA
KNSA
Revenue
$346.7M
$202.1M
Net Profit
$53.3M
$14.2M
Gross Margin
87.5%
89.6%
Operating Margin
17.9%
9.8%
Net Margin
15.4%
7.0%
Revenue YoY
-2.9%
65.0%
Net Profit YoY
-21.4%
259.8%
EPS (diluted)
$0.55
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DLB
DLB
KNSA
KNSA
Q4 25
$346.7M
$202.1M
Q3 25
$307.0M
$180.9M
Q2 25
$315.5M
$156.8M
Q1 25
$369.6M
$137.8M
Q4 24
$357.0M
$122.5M
Q3 24
$304.8M
$112.2M
Q2 24
$288.8M
$108.6M
Q1 24
$364.5M
$79.9M
Net Profit
DLB
DLB
KNSA
KNSA
Q4 25
$53.3M
$14.2M
Q3 25
$49.3M
$18.4M
Q2 25
$46.1M
$17.8M
Q1 25
$91.8M
$8.5M
Q4 24
$67.8M
$-8.9M
Q3 24
$58.6M
$-12.7M
Q2 24
$38.4M
$-3.9M
Q1 24
$97.8M
$-17.7M
Gross Margin
DLB
DLB
KNSA
KNSA
Q4 25
87.5%
89.6%
Q3 25
87.1%
88.8%
Q2 25
86.1%
88.1%
Q1 25
90.3%
87.0%
Q4 24
88.6%
85.4%
Q3 24
88.8%
82.1%
Q2 24
87.7%
88.7%
Q1 24
89.4%
86.7%
Operating Margin
DLB
DLB
KNSA
KNSA
Q4 25
17.9%
9.8%
Q3 25
9.7%
13.3%
Q2 25
15.1%
12.9%
Q1 25
29.2%
9.6%
Q4 24
22.4%
-15.7%
Q3 24
15.2%
-8.6%
Q2 24
12.7%
-0.1%
Q1 24
29.9%
-20.7%
Net Margin
DLB
DLB
KNSA
KNSA
Q4 25
15.4%
7.0%
Q3 25
16.1%
10.2%
Q2 25
14.6%
11.4%
Q1 25
24.8%
6.2%
Q4 24
19.0%
-7.3%
Q3 24
19.2%
-11.3%
Q2 24
13.3%
-3.6%
Q1 24
26.8%
-22.2%
EPS (diluted)
DLB
DLB
KNSA
KNSA
Q4 25
$0.55
$0.18
Q3 25
$0.50
$0.23
Q2 25
$0.48
$0.23
Q1 25
$0.94
$0.11
Q4 24
$0.70
$-0.11
Q3 24
$0.59
$-0.18
Q2 24
$0.40
$-0.06
Q1 24
$1.01
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DLB
DLB
KNSA
KNSA
Cash + ST InvestmentsLiquidity on hand
$644.6M
$414.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.6B
$567.6M
Total Assets
$3.2B
$763.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DLB
DLB
KNSA
KNSA
Q4 25
$644.6M
$414.1M
Q3 25
$702.6M
$352.1M
Q2 25
$699.3M
$307.8M
Q1 25
$626.6M
$268.3M
Q4 24
$520.8M
$243.6M
Q3 24
$482.0M
$223.8M
Q2 24
$869.0M
$218.8M
Q1 24
$825.4M
$213.6M
Stockholders' Equity
DLB
DLB
KNSA
KNSA
Q4 25
$2.6B
$567.6M
Q3 25
$2.6B
$535.4M
Q2 25
$2.6B
$495.0M
Q1 25
$2.6B
$457.5M
Q4 24
$2.5B
$438.4M
Q3 24
$2.5B
$437.0M
Q2 24
$2.4B
$435.1M
Q1 24
$2.4B
$431.9M
Total Assets
DLB
DLB
KNSA
KNSA
Q4 25
$3.2B
$763.6M
Q3 25
$3.2B
$712.3M
Q2 25
$3.2B
$661.1M
Q1 25
$3.2B
$599.3M
Q4 24
$3.2B
$580.6M
Q3 24
$3.1B
$555.3M
Q2 24
$3.0B
$542.4M
Q1 24
$3.0B
$519.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DLB
DLB
KNSA
KNSA
Operating Cash FlowLast quarter
$54.8M
$53.9M
Free Cash FlowOCF − Capex
$50.2M
$53.3M
FCF MarginFCF / Revenue
14.5%
26.4%
Capex IntensityCapex / Revenue
1.3%
0.3%
Cash ConversionOCF / Net Profit
1.03×
3.80×
TTM Free Cash FlowTrailing 4 quarters
$715.3M
$136.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DLB
DLB
KNSA
KNSA
Q4 25
$54.8M
$53.9M
Q3 25
$472.2M
$33.7M
Q2 25
$67.7M
$28.1M
Q1 25
$174.9M
$22.3M
Q4 24
$106.8M
$18.8M
Q3 24
$327.3M
$-2.2M
Q2 24
$21.3M
$5.2M
Q1 24
$181.4M
$4.0M
Free Cash Flow
DLB
DLB
KNSA
KNSA
Q4 25
$50.2M
$53.3M
Q3 25
$435.9M
$33.0M
Q2 25
$61.3M
$27.9M
Q1 25
$168.0M
$22.2M
Q4 24
$100.0M
$18.6M
Q3 24
$297.2M
Q2 24
$13.7M
Q1 24
$172.5M
$3.9M
FCF Margin
DLB
DLB
KNSA
KNSA
Q4 25
14.5%
26.4%
Q3 25
142.0%
18.2%
Q2 25
19.4%
17.8%
Q1 25
45.5%
16.1%
Q4 24
28.0%
15.2%
Q3 24
97.5%
Q2 24
4.7%
Q1 24
47.3%
4.9%
Capex Intensity
DLB
DLB
KNSA
KNSA
Q4 25
1.3%
0.3%
Q3 25
11.8%
0.4%
Q2 25
2.0%
0.1%
Q1 25
1.9%
0.1%
Q4 24
1.9%
0.2%
Q3 24
9.8%
0.0%
Q2 24
2.6%
0.0%
Q1 24
2.4%
0.1%
Cash Conversion
DLB
DLB
KNSA
KNSA
Q4 25
1.03×
3.80×
Q3 25
9.57×
1.83×
Q2 25
1.47×
1.58×
Q1 25
1.91×
2.61×
Q4 24
1.57×
Q3 24
5.59×
Q2 24
0.55×
Q1 24
1.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DLB
DLB

Licensing Brodcast Revenue$100.3M29%
Licensing Mobile Revenue$74.9M22%
Licensing Other Revenue$70.2M20%
Licensing CE Revenue$45.6M13%
Licensing PC Revenue$28.7M8%
Products And Services$26.9M8%

KNSA
KNSA

Segment breakdown not available.

Related Comparisons